Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab + HDMP in CLL
NCT02229422Phase 2Active, not recruiting
- Sponsor
- University of California, San Diego
- Start
- Sep 2014
- Primary completion
- Oct 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of obinutuzumab in chronic lymphocytic leukemia (CLL), sponsored by University of California, San Diego. Primary endpoints: Dose Limiting Toxicity at 2 months and Response assessment based on IWCLL at 2 months. Started Sep 2014; status: active, not recruiting.
02
Drugs
obinutuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02229422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02229422.